Lesson
Recognize the Herpesvirus Decision State
HSV and VZV establish sensory-ganglion latency, but the immediate decision depends on syndrome, compartment, host, trajectory, and emergency signs.
- HSV latency
- VZV reactivation
- Lesion testing
- Emergency sign
- Transmission
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Map latency and recurrence
HSV persists in sensory ganglia and can reactivate with or without visible lesions. VZV causes varicella, then can reactivate later as herpes zoster. Antiviral treatment controls productive replication but does not remove latent viral genomes.
Recognize the pattern
Localized oral or genital HSV and unilateral dermatomal zoster can be clinically recognizable. Lesion nucleic acid amplification testing can confirm and type disease when results change counseling, longitudinal care, or differential diagnosis.
Escalate dangerous compartments
Eye pain or vision change, facial weakness or ear symptoms, dissemination, pregnancy with new genital disease, neonatal exposure, meningismus, altered mental status, focal deficit, seizure, visceral disease, or hemodynamic instability requires urgent evaluation.
Interpret testing carefully
A negative test from an old or healing lesion does not exclude infection absolutely. Lesion stage, sampling quality, viral burden, prior treatment, and the competing diagnosis shape interpretation.
Quick check
Lesson
Activate the Antiviral Inside the Infected Cell
Viral thymidine kinase begins selective activation, host kinases complete triphosphate formation, and the active nucleotide inhibits herpesvirus DNA polymerase.
- Viral thymidine kinase
- Host kinase
- Triphosphate
- DNA polymerase
- Cross resistance
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Begin with viral kinase
HSV or VZV thymidine kinase performs the first phosphorylation of acyclovir or penciclovir. This concentrates activation in infected cells and creates a major source of selective toxicity.
Complete activation
Cellular kinases convert the monophosphate to the active triphosphate. Acyclovir triphosphate and penciclovir triphosphate then compete at viral DNA polymerase and impair viral DNA elongation.
Predict resistance
Loss or alteration of viral thymidine kinase can cause resistance to acyclovir and valacyclovir and often famciclovir. Viral DNA polymerase changes can also reduce susceptibility.
Investigate failure
Review diagnosis, start time, adherence, absorption, dose, renal adjustment, immune status, compartment, and lesion progression. When resistance remains likely, obtain a viral culture for phenotypic sensitivity and involve infectious disease expertise.
Quick check
Lesson
Connect Acyclovir Structure to Viral Arrest
Acyclovir is an acyclic guanine nucleoside analogue whose active triphosphate preferentially arrests herpesvirus DNA synthesis.
- Guanine analogue
- Acyclic scaffold
- Triphosphate
- Chain termination
- Renal elimination
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Read the scaffold
Acyclovir mimics guanosine but uses an acyclic side chain rather than a conventional sugar. It is not administered as a preformed active nucleotide and must undergo viral and host phosphorylation.
Stop viral DNA synthesis
Acyclovir triphosphate competitively inhibits viral DNA polymerase, enters viral DNA, terminates chain growth, and can trap the polymerase complex. Selective activation and target preference limit nonspecific host DNA toxicity.
Distinguish HSV and VZV
HSV thymidine kinase phosphorylates acyclovir more efficiently than VZV thymidine kinase. VZV syndromes therefore use exposure regimens distinct from routine mucocutaneous HSV.
Follow the kidneys
Acyclovir is eliminated mainly unchanged in urine. Falling kidney function lengthens half-life and raises renal and neurologic toxicity risk, so indication, route, kidney function, hydration, and dialysis must be verified together.
Quick check
Lesson
Build a Safe Intravenous Acyclovir System
Intravenous acyclovir requires dilution, at least a one-hour infusion, hydration, renal adjustment, daily surveillance, and rapid response to renal or neurologic change.
- Dilution
- One-hour infusion
- Hydration
- Crystal nephropathy
- Neurotoxicity
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Prepare the infusion
Dilute the calculated dose in a compatible solution to an appropriate final concentration, commonly about 7 mg per mL or lower, and infuse over at least one hour. Never administer the vial volume as a rapid intravenous push.
Prevent crystal injury
High intratubular acyclovir concentration can exceed solubility and precipitate. Verify hydration, urine output, infusion rate, dose, interval, concentration, nephrotoxins, and baseline and changing creatinine.
Recognize neurotoxicity
Renal accumulation can cause lethargy, confusion, hallucinations, agitation, tremor, seizure, or coma. Toxic encephalopathy can resemble HSV encephalitis, so dose history, renal trend, examination, imaging, cerebrospinal fluid, and dialysis need must be reviewed urgently.
Use accountable weight policy
Current labeling provides weight-based dosing and renal intervals but does not establish one universal obesity scalar for every patient. Follow the current label and an accountable institutional obesity protocol rather than treating an older blanket ideal-body-weight statement as universal.
Quick check
Lesson
Use Valacyclovir as an Exposure Prodrug
Valacyclovir is the L-valyl ester of acyclovir. Rapid conversion improves oral acyclovir exposure but preserves acyclovir renal, neurologic, and hypersensitivity concerns.
- L-valyl ester
- Acyclovir exposure
- Syndrome dose
- Renal table
- Hydration
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Activate the prodrug
Valacyclovir is rapidly converted to acyclovir and L-valine. Acyclovir bioavailability after valacyclovir is about 54.5 percent, food does not meaningfully alter exposure, and CYP metabolism is not the dominant disposition pathway.
Separate syndrome regimens
Current adult labeling uses 2 grams every 12 hours for one day for cold sores, 500 mg twice daily for three days for recurrent genital herpes, 1 gram daily for suppression, and 1 gram three times daily for seven days for zoster. First-episode genital dosing differs between the current label and CDC duration.
Adjust by indication
Use the indication-specific renal table because standard exposures differ. Hemodialysis dosing is administered after dialysis. Preserve hydration and review older age, nephrotoxins, and central nervous system findings.
Recognize serious harm
Acute renal failure, central nervous system effects, anaphylaxis, severe cutaneous reactions, and rare thrombotic microangiopathy in severely immunocompromised high-dose populations require prompt recognition and action.
Quick check
Lesson
Convert Famciclovir to Penciclovir
Famciclovir is converted by deacetylation and oxidation to penciclovir, whose intracellular triphosphate inhibits herpesvirus DNA polymerase.
- Diacetyl prodrug
- Aldehyde oxidase
- Penciclovir triphosphate
- Labeled scope
- Renal adjustment
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Trace conversion
Famciclovir is a diacetyl 6-deoxy prodrug converted through deacetylation and aldehyde-oxidase-mediated oxidation to penciclovir. Viral thymidine kinase and host kinases then produce penciclovir triphosphate.
Interpret intracellular persistence
Penciclovir triphosphate persists in infected cells and inhibits viral DNA polymerase without the same obligatory chain-termination pattern as acyclovir. Persistence supports brief regimens but does not eradicate latency.
Use the current regimen
Current adult labeling includes 1500 mg once for recurrent labialis, 1 gram twice in one day for recurrent genital herpes, 250 mg twice daily for suppression, and 500 mg every eight hours for seven days for zoster, all before renal adjustment.
Distinguish label and guideline
The current label says efficacy is not established for a first genital episode, while CDC includes famciclovir 250 mg three times daily for 7 to 10 days. Document which authority supports the choice. Monitor renal function, headache, nausea, confusion, hypersensitivity, and severe skin reactions.
Quick check
Lesson
Treat Herpes Labialis at the Earliest Signal
Episodic therapy has the greatest opportunity during prodrome or at the first lesion, when active viral replication is still early.
- Prodrome
- One-day regimen
- Topical boundary
- Self administration
- Transmission
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Recognize the start signal
Tingling, itching, burning, or pain can precede the lesion. Confirm recurrence pattern, location, onset, immune status, pregnancy, kidney function, interactions, and whether eye or intraoral disease changes the plan.
Choose systemic exposure
Eligible recurrent labialis can use valacyclovir 2 grams every 12 hours for one day or famciclovir 1500 mg once, with renal adjustment. The valacyclovir cold-sore course ends after two doses.
Keep topical therapy local
Topical acyclovir or penciclovir can offer a modest benefit when started early but requires frequent application. Topical skin products are not treatment for ocular, intraoral, disseminated, or invasive infection.
Reduce spread
HSV can shed without visible lesions. Avoid kissing and oral contact during symptoms, avoid sharing contaminated items, use hand hygiene, protect the eye from hand transfer, and do not promise that therapy makes lesions noncontagious.
Quick check
Lesson
Build Longitudinal Genital Herpes Care
Genital herpes care separates first episode, episodic recurrence, daily suppression, transmission reduction, pregnancy, partner counseling, and severe disease.
- First episode
- Episodic plan
- Suppression
- Transmission reduction
- Annual reassessment
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Treat every first episode
CDC recommends systemic therapy for every first clinical episode because initially mild disease can become severe or prolonged. Recommended regimens use acyclovir 400 mg three times daily, famciclovir 250 mg three times daily, or valacyclovir 1 gram twice daily for 7 to 10 days, with extension if healing is incomplete.
Prepare episodic treatment
Recurrent treatment works best during prodrome or within one day of lesion onset. Prescribe an on-hand regimen, verify renal function, and give clear start and stop instructions before the next recurrence.
Use suppression intentionally
Daily acyclovir, valacyclovir, or famciclovir reduces symptomatic recurrences and can improve quality of life. Valacyclovir 500 mg daily can be less effective with at least 10 recurrences per year. Reassess goals periodically rather than presenting suppression as cure.
Reduce but do not erase transmission
Valacyclovir 500 mg daily can reduce transmission in selected discordant couples. Combine it with disclosure, condoms, and avoiding sexual activity during lesions or prodrome because asymptomatic shedding persists.
Quick check
Lesson
Escalate Invasive HSV and Perinatal Risk
Central nervous system, visceral, disseminated, maternal, delivery, and neonatal HSV decisions require urgent syndrome-specific intravenous care and shared specialty ownership.
- Encephalitis
- Severe HSV
- Pregnancy
- Delivery
- Neonatal HSV
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Treat suspected encephalitis
Fever, altered mental status, focal findings, or seizure can represent HSV encephalitis. Begin urgent empiric intravenous acyclovir while neurologic evaluation, imaging, cerebrospinal fluid testing, renal verification, and infusion planning proceed.
Manage severe disease
Disseminated infection, hepatitis, pneumonitis, meningitis, or other hospitalized severe HSV requires intravenous acyclovir. CDC uses 5 to 10 mg per kg every eight hours for severe adult disease, with renal adjustment, followed by syndrome-specific completion.
Use current pregnancy evidence
Acyclovir has extensive pregnancy experience and is believed safe across trimesters and during breastfeeding. CDC recommends suppressive acyclovir 400 mg three times daily or valacyclovir 500 mg twice daily beginning at 36 weeks for recurrent genital herpes, with obstetric delivery planning.
Protect the newborn
Known or suspected neonatal HSV requires urgent specialist evaluation and intravenous acyclovir 20 mg per kg every eight hours. CDC describes 14 days for disease limited to skin and mucosa and 21 days for disseminated or central nervous system disease, with age-specific renal and monitoring ownership.
Quick check
Lesson
Treat Zoster and Prevent the Next Episode
Herpes zoster treatment combines early antiviral exposure, complication triage, pain care, and recombinant vaccination after the acute episode.
- Dermatome
- Early treatment
- Higher exposure
- Complication
- Shingrix
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Recognize reactivation
Painful unilateral dermatomal vesicles support zoster, but distribution, new lesions, immune status, age, eye or ear symptoms, dissemination, breathing, mental status, and competing diagnoses determine urgency.
Treat early
Acyclovir, valacyclovir, or famciclovir can accelerate lesion resolution and reduce acute pain. Benefit is greatest when treatment starts promptly, ideally within 72 hours. Ongoing new lesions or high-risk disease can still require treatment after that window.
Use a zoster regimen
Current adult regimens include valacyclovir 1 gram three times daily or famciclovir 500 mg every eight hours for seven days, with indication-specific renal adjustment. Do not reuse a genital-suppression or cold-sore dose.
Prevent recurrence and complications
Address acute pain and postherpetic neuralgia risk. CDC recommends two-dose recombinant zoster vaccine for adults age 50 and older and immunocompromised adults age 19 and older, including after prior shingles or Zostavax. Do not vaccinate during active shingles.
Quick check
Lesson
Close the Herpesvirus Treatment Loop
A safe plan connects virus, syndrome, compartment, host, timing, product, activation, exposure, kidney function, safety, prevention, response, and follow-up ownership.
- Syndrome
- Exposure
- Kidney function
- Failure audit
- Follow-up
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Verify the complete order
Confirm HSV or VZV syndrome, first or recurrent state, site, severity, immune status, pregnancy, age, product, route, dose, interval, duration, start window, kidney function, dialysis, hydration, and delivery technique.
Monitor shared risks
Acyclovir exposure joins acyclovir and valacyclovir renal and neurologic safety. Penciclovir exposure makes famciclovir renal adjustment essential. Stop and evaluate anaphylaxis, angioedema, blistering skin, mucosal injury, progressive renal change, or neurologic decline.
Audit treatment failure
Review diagnosis, timing, adherence, absorption, delivery, renal underdosing or accumulation, immune status, compartment, ongoing lesions, resistance, source control, and follow-up. Do not label every slow lesion resistant.
Use current evidence
This module supports structured verification but does not replace patient-specific diagnosis, current CDC guidance, current product labeling, local protocols, specialty consultation, or qualified prescribing.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 192 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.